NewAmsterdam Pharma Co NV
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
The financial statements of the Company are contained on pages F-1 through F-27 of this Annual Report and are incorporated herein by reference.
Selected quarterly financial data is presented below for each quarter in fiscal year 2023 to reflect the Company's material retrospective change due to its conversion from IFRS to U.S. GAAP.
| For the three months ended | ||||
|---|---|---|---|---|
| March 31,2023 | June 30,2023 | September 30, 2023 | December 31, 2023 | |
| (In thousands of USD, except per share amounts) | ||||
| Revenue | 8,629 | 1,717 | 2,941 | 803 |
| Operating expenses: | ||||
| Research and development expenses | 40,420 | 34,341 | 43,371 | 41,292 |
| Selling, general and administrative expenses | 8,062 | 9,858 | 9,128 | 10,585 |
| Total operating expenses | 48,482 | 44,199 | 52,499 | 51,877 |
| Operating loss | (39,853) | (42,482) | (49,558) | (51,074) |
| Loss for the period | (42,018) | (38,292) | (47,132) | (49,495) |
| Net loss per ordinary share | ||||
| Basic and diluted | $(0.51) | $(0.47) | $(0.57) | $(0.60) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.